Search Results
Jun 06, 2026, 13:14 ET Rosen Law Firm Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation - PFSI
https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class
More news about: THE ROSEN LAW FIRM, P. A.
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with established CVD with overweight or obesity with no prior history of diabetes.10 In SELECT, established CVD was defined as a prior heart attack, prior stroke, or symptomatic PAD.10 The trial,
More news about: NOVO NORDISK INC.
Jun 06, 2026, 11:57 ET /C O R R E C T I O N -- U.S. Postal Service/
USA Philatelic or at Post Office locations nationwide. For officially licensed stamp products, shop the
More news about: U.S. Postal Service
Jun 06, 2026, 11:08 ET MONDAY INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - MEDP
alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Medpace consistently oversold Medpace's projected book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's
More news about: Robbins Geller Rudman & Dowd LLP
Jun 06, 2026, 11:06 ET In HelloNation, Periodontics Expert Dr. Scott Kissel of Manhattan, NY, Details Why Microsurgical Techniques Matter in Periodontal Care
protects healthy bone.These same principles apply in regenerative procedures as well. The article emphasizes that when the goal is to rebuild tissue or bone, accuracy is essential. Microsurgical techniques help create the conditions needed for rapid healing and tissue growth.Not every treatment
More news about: HelloNation
Jun 06, 2026, 11:00 ET MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Stellantis N.V. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - STLA
worldwide.The Stellantis class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Stellantis'
More news about: Robbins Geller Rudman & Dowd LLP
Jun 06, 2026, 10:30 ET INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Simparica Trio.The Zoetis class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening
More news about: Robbins Geller Rudman & Dowd LLP
Jun 06, 2026, 10:20 ET AVAV INVESTOR NOTICE: AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
conducting telemetry, or accessing data from satellites to assess their status and health, according to the complaint.The AeroVironment class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
More news about: Robbins Geller Rudman & Dowd LLP
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
included were adults with type 2 diabetes with a prescription claim for semaglutide 1 mg with subsequent claims for either semaglutide 2 mg or tirzepatide 2.5 mg or 5 mg. The study included 64,888 adults in an HbA1c cohort and 56,852 in a weight‑loss cohort. As with all observational analyses,
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
included were adults with type 2 diabetes with a prescription claim for semaglutide 1 mg with subsequent claims for either semaglutide 2 mg or tirzepatide 2.5 mg or 5 mg. The study included 64,888 adults in an HbA1c cohort and 56,852 in a weight‑loss cohort. As with all observational analyses,
More news about: Novo Nordisk
Jun 06, 2026, 09:00 ET Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) across patient populations—including in individuals with excess weight or obesity with or without type 2 diabetes—and dosage levels, ranging from weekly to monthly. The data were presented during symposium sessions at the 2026 Scientific
More news about: American Diabetes Association
Jun 06, 2026, 09:00 ET New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Association notes that high ketone levels can escalate to DKA within hours and, if left untreated, can lead to coma or death.2 Many people living with diabetes aren't familiar with DKA or its symptoms, despite clinical guidance recommending ketone testing during periods of elevated glucose, making
More news about: Abbott
Jun 06, 2026, 07:51 ET Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded
technology-driven world. And that's going to add lot of value to the students and to the nation and also to the industry because you will get learners or candidates who are prepared for the role that industry is looking out for."Parkar added, "If we look at as a firm we look at contributing to Viksit
More news about: Chandigarh University
Jun 06, 2026, 06:00 ET Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice
lensesFor members seeking additional features, such as progressive lenses or anti-reflective coatings, plans may offer fixed copays or additional savings on upgrades. In some cases, enhanced plan options provide full or reduced-cost access to these features.This layered approach to lens coverage
More news about: BetterBusinessAdvice.com
Jun 05, 2026, 23:03 ET PICS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PicS N.V. and Announces Opportunity for Investors with Substantial Losses to Lead the PicS N.V. Class Action Lawsuit
million.The PicS N.V. class action lawsuit alleges that defendants in the IPO's offering documents made false and/or misleading statements and/or failed to disclose that: (i) PicS N.V. had conducted an evaluation of its credit evaluation procedures in December 2025 and determined
More news about: Robbins Geller Rudman & Dowd LLP
Jun 05, 2026, 22:12 ET NYT Investors Have the Opportunity to Join Investigation of The New York Times Company with the Schall Law Firm
shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in The New York Times Company ("New York Times" or "the Company") (NYSE:
More news about: The Schall Law Firm
Jun 05, 2026, 22:00 ET Lockheed Martin Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lockheed Martin Corporation - LMT
investigation is focusing on whether Lockheed's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Lockheed shares and would
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET Roblox Investigation Initiated: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation - RBLX
Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit us at
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 21:02 ET Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State
programs, staffing, school improvement and leadership development for teachers and school administrators.For more information, call (888) 485-THINK or visit
More news about: Think Together
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Ucp1-driven thermogenesis, Ractigen Therapeutics is establishing a highly differentiated therapeutic mechanism that can act as a standalone treatment or as the ideal combination partner for existing incretin therapies.The abstract is available online via the journal Diabetes® website.Presentation
More news about: Ractigen Therapeutics
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Ambrosia undertakes no obligation to revise or publicly release the results of any revision
More news about: Ambrosia Biosciences
Jun 05, 2026, 19:30 ET Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
cure diabetes—and we're not stopping. There are over 155 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at
More news about: American Diabetes Association
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
zenagamtide (ranging from 0.4 mg to 40 mg) versus matched placebo in 262 adults with type 2 diabetes inadequately controlled (A1C 7.0–10.0%) on metformin, with or without an SGLT2 inhibitor. The study met its primary endpoint of change in A1C across all doses and also key supportive secondary endpoint of change
More news about: NOVO NORDISK INC.